ARTICLE | Product Development
WHO green light for GSK malaria vaccine culminates 30 years of R&D
First vaccine against human parasitic disease could save 22,000 lives per year
October 6, 2021 10:52 PM UTC
The WHO’s recommendation for widespread use of GSK’s RTS,S malaria vaccine marks the completion of a 30-year vaccine R&D program and the start of what could be a major advance in public health.
RTS,S/AS01, developed by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) with non-profit global health organization PATH and a network of African research centers, could prevent tens of thousands of deaths of children in sub-Saharan Africa every year and improve the health of hundreds of thousands. ...